Peter Sand to Botulinum Toxins, Type A
This is a "connection" page, showing publications Peter Sand has written about Botulinum Toxins, Type A.
Connection Strength
0.880
-
Botulinum toxin A in the overactive bladder: current status and future directions. BJU Int. 2007 Feb; 99(2):247-62.
Score: 0.283
-
OnabotulinumtoxinA for the Treatment of Patients with Overactive Bladder and Urinary Incontinence: Results of a Phase 3, Randomized, Placebo Controlled Trial. J Urol. 2017 02; 197(2S):S216-S223.
Score: 0.141
-
Durable Efficacy and Safety of Long-Term OnabotulinumtoxinA Treatment in Patients with Overactive Bladder Syndrome: Final Results of a 3.5-Year Study. J Urol. 2016 Sep; 196(3):791-800.
Score: 0.134
-
OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol. 2013 Jun; 189(6):2186-93.
Score: 0.106
-
Treatment satisfaction and goal attainment with onabotulinumtoxinA in patients with incontinence due to idiopathic OAB. Int Urogynecol J. 2012 Aug; 23(8):1017-25.
Score: 0.100
-
Evaluation and treatment of female urinary incontinence. Minerva Urol Nefrol. 2007 Dec; 59(4):431-50.
Score: 0.075
-
Surgery for urinary incontinence in women: Report from the 6th international consultation on incontinence. Neurourol Urodyn. 2019 02; 38(2):825-837.
Score: 0.040